Kowa Announces Subgroup Analyses of Peretinoin (NIK-333) Phase II/III Trial in Patients Following Curative Therapy for Hepatocellular Carcinoma (HCC) Indicate Populations Who May Gain Most Benefit from Peretinoin Therapy